Randy Osborne

The Sought-After Validation' Deal: Must Enter With Caution

Oct. 17, 2003

By Randy Osborne

Biotech Comes On Strong: 'Second-Best' Year Ever?

Oct. 16, 2003

By Randy Osborne

Elixir Pharmaceuticals Gets $19M In Second B' Round

Oct. 14, 2003

By Randy Osborne

Corgentech, BMS Enter Graft Deal Valued At Up To $250M

Oct. 14, 2003

By Randy Osborne

With two Phase III trials under way testing its treatment to prevent vein-graft failure after surgery, Corgentech Inc. is joining with Bristol-Myers Squibb Co. in a deal that's expected to get revenue flowing better. (BioWorld Today)

New Phase III Shows Cialis Helps After Prostate Surgery

Oct. 13, 2003

By Randy Osborne

Cialis Marketing, Price Strategy Puts New Spin On Battle In ED

Oct. 13, 2003

By Randy Osborne

Money might not buy love but, as Pfizer Inc.'s blockbuster Viagra proved, it can do wonders for sexual capability in men who have the wherewithal to pay for the magic blue pill. Talk about "hard cash." (BioWorld Financial Watch)

OrthoLogic Selling Bone-Growth Platform, Focusing On Chrysalin

Oct. 10, 2003

By Randy Osborne

Acusphere's $52.5M Pricing Likely Is Not IPO Bellwether

Oct. 9, 2003

By Randy Osborne

With an ultrasound imaging agent in Phase III, Acusphere Inc. became the first kernel of corn to pop in the IPO pan, raising $52.5 million by pricing its 3.75 million shares at $14 - the mid-point of its targeted $13 to $15 range. (BioWorld Today)